High sulfation and a high molecular weight are important for anti-hepcidin activity of heparin

Frontiers in Pharmacology

Volumn 6, Issue JAN, 2016, Pages

  Asperti, Michela ^a   Naggi, Annamaria ^b   Esposito, Emiliano ^b   Ruzzenenti, Paola ^a   Di Somma, Margherita ^a   Gryzik, Magdalena ^a   Arosio, Paolo ^a   Poli, Maura ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

Author keywords

2 O and 6 O sulfated heparins; Anemia of chronic diseases; BMP6; Hepcidin; Iron metabolism; Low molecular weight heparins

Indexed keywords

GLUCOSAMINE; HEPARIN; HEPCIDIN; IDURONIC ACID;

ACETYLATION; ANTIHEPCIDIN ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG DETERMINATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SULFATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

EID: 84962034386     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00316     Document Type: Article

References (19)

1. Babitt, J., Huang, F., Wrighting, D., Xia, Y., Sidis, Y., Samad, T., et al. (2006). Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet. 38, 531-539. doi: 10.1038/ng1777
2. Babitt, J. L., Huang, F. W., Xia, Y., Sidis, Y., Andrews, N. C., and Lin, H. Y. (2007). Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J. Clin. Invest. 117, 1933-1939. doi: 10.1172/JCI31342
3. Bertini, S., Bisio, A., Torri, G., Bensi, D., and Terbojevich, M. (2005). Molecular weight determination of heparin and dermatan sulfate by size exclusion chromatography with a triple detector array. Biomacromolecules 6, 168-173. doi: 10.1021/bm049693s
4. Casu, B., and Gennaro, U. (1975). A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydr. Res. 39, 168-176. doi: 10.1016/S0008-6215(00)82654-3
5. Core, A. B., Canali, S., and Babitt, J. L. (2014). Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis. Front. Pharmacol. 5:104. doi: 10.3389/fphar.2014.00104
6. Fung, E., and Nemeth, E. (2013). Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 98, 1667-1676. doi: 10.3324/haematol.2013.084624
7. Ganz, T., and Nemeth, E. (2011). Hepcidin and disorders of iron metabolism. Annu. Rev. Med. 62, 347-360. doi: 10.1146/annurev-med-050109-142444
8. Ganz, T., and Nemeth, E. (2012). Hepcidin and iron homeostasis. Biochim. Biophys. Acta 1823, 1434-1443. doi: 10.1016/j.bbamcr.2012.01.014
9. Guerrini, M., Naggi, A., Guglieri, S., Santarsiero, R., and Torri, G. (2005). Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal. Biochem. 337, 35-47. doi: 10.1016/j.ab.2004.10.012
10. Hentze, M. W., Muckenthaler, M. U., Galy, B., and Camaschella, C. (2010). Two to tango: regulation of Mammalian iron metabolism. Cell 142, 24-38. doi: 10.1016/j.cell.2010.06.028
11. Kuo, W. J., Digman, M. A., and Lander, A. D. (2010). Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization. Mol. Biol. Cell 21, 4028-4041. doi: 10.1091/mbc. E10-04-0348
12. Mulloy, B., Forster, M. J., Jones, C., and Davies, D. B. (1993). N.m.r. and molecular-modelling studies of the solution conformation of heparin. Biochem. J. 293(Pt 3), 849-858. doi: 10.1042/bj2930849
13. Naggi, A., Casu, B., Perez, M., Torri, G., Cassinelli, G., Penco, S., et al. (2005). Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J. Biol. Chem. 280, 12103-12113. doi: 10.1074/jbc. M414217200
14. Poli, M., Asperti, M., Naggi, A., Campostrini, N., Girelli, D., Corbella, M., et al. (2014a). Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood 123, 1564-1573. doi: 10.1182/blood-2013-07-515221
15. Poli, M., Asperti, M., Ruzzenenti, P., Mandelli, L., Campostrini, N., Martini, G., et al. (2014b). Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo. Biochem. Pharmacol. 92, 467-475. doi: 10.1016/j.bcp.2014.09.007
16. Poli, M., Asperti, M., Ruzzenenti, P., Regoni, M., and Arosio, P. (2014c). Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front. Pharmacol. 5:86. doi: 10.3389/fphar.2014.00086
17. Poli, M., Girelli, D., Campostrini, N., Maccarinelli, F., Finazzi, D., Luscieti, S., et al. (2011). Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood 117, 997-1004. doi: 10.1182/blood-2010-06-289082
18. Verga Falzacappa, M. V., Vujic Spasic, M., Kessler, R., Stolte, J., Hentze, M. W., and Muckenthaler, M. U. (2007). STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109, 353-358. doi: 10.1182/blood-2006-07-033969
19. Zhao, N., Zhang, A. S., and Enns, C. A. (2013). Iron regulation by hepcidin. J. Clin. Invest. 123, 2337-2343. doi: 10.1172/JCI67225